

Personalized mRNA Neoantigen Vaccine

□ Personalized mRNA Neoantigen Vaccine

A **personalized mRNA neoantigen vaccine** is a cutting-edge **cancer immunotherapy** designed to stimulate a targeted **immune response** against **neoantigens**—unique tumor-specific mutations—using **messenger RNA (mRNA)** technology.

⚙️ How the Vaccine Works

1. ****[[Tumor biopsy]] and [[sequencing]]**** → identify patient-specific mutations
2. ****Bioinformatic prediction**** → select immunogenic neoantigens
3. ****[[mRNA synthesis]]**** → encode selected neoantigens
4. ****Delivery**** → Inject the mRNA (typically in lipid nanoparticles)
5. ****Immune activation****:
 - Host cells translate mRNA into neoantigen peptides
 - Peptides are presented via MHC I and II
 - Activation of ****CD8⁺ cytotoxic T cells**** and ****CD4⁺ helper T cells****

□ Advantages

- **Personalized** → tailored to the unique mutations of each patient
- **Specific and safe** → minimal risk of autoimmunity
- **Flexible and rapid** production pipeline
- **Non-integrating** → lower genomic risk
- Suitable for **combination with checkpoint inhibitors**

□ Clinical Trials & Research

- **NOA-16 Trial** (Glioblastoma, Germany)
 1. First-in-human personalized mRNA neoantigen vaccine
 2. Induced T cell responses, well-tolerated
- **Moderna mRNA-4157 + pembrolizumab**
 1. Phase II trial in melanoma showed reduced risk of recurrence
- Platforms under development by **BioNTech**, **CureVac**, **Moderna**

⚠️ Challenges

1. Requires **tumor sequencing** and rapid **bioinformatic analysis**
2. **Logistically complex**: personalized production per patient

3. **Costly**, though expected to improve with automation
4. Tumor **immune evasion** and **heterogeneity** remain issues

□ Future Directions

- Integration with **AI for neoantigen selection**
- Expansion into **preventive oncology** (e.g., hereditary cancer syndromes)
- Combination with:
 1. **Checkpoint inhibitors**
 2. **Oncolytic viruses**
 3. **Radiotherapy**

□ Summary

The **personalized mRNA neoantigen vaccine** represents a revolutionary approach in oncology. By leveraging tumor-specific mutations and mRNA technology, it delivers **precise, patient-specific immunity** with the potential to transform the treatment of **highly aggressive and heterogeneous tumors** such as glioblastoma and melanoma.

From:
<https://neurosurgerywiki.com/wiki/> - Neurosurgery Wiki

Permanent link:
https://neurosurgerywiki.com/wiki/doku.php?id=personalized_mrna_neoantigen_vaccine

Last update: **2025/03/26 05:35**

